Study of OB-002 in Patients With Refractory Metastatic Cancer

Phase 1 Withdrawn Orion Biotechnology

Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two or more treatment regimens.

Timeline

Start: 2024-01
Primary completion: 2025-04
Completion: 2025-08

Outcome

Outcome not reported

Stopped: “study terminated due to changes in the drug development plan”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OB-002	Unknown	0.25 mg/kg	—
Subject	OB-002	Unknown	0.5 mg/kg	—
Subject	OB-002	Unknown	1 mg/kg	—
Subject	OB-002	Unknown	1.5 mg/kg	—

Study of OB-002 in Patients With Refractory Metastatic Cancer

Summary

Timeline

Outcome

Drugs

Indications